Literature DB >> 24172661

Warfarin associated intracerebral hemorrhage in Hong Kong Chinese.

K C Teo, N R Mahboobani, R Lee, C W Siu, R T F Cheung, S L Ho, K K Lau, K H Chan.   

Abstract

OBJECTIVES: Warfarin-associated intracerebral hemorrhage (WICH) is a serious neurological condition associated with significant mortality and morbidity. We aimed to study the clinical features and factors that predict clinical outcome of Chinese patients with WICH.
METHODS: Medical records of patients with spontaneous intracerebral hemorrhage (ICH) admitted to our hospital between July 2001 and June 2010 were reviewed and those with WICH were studied in detail retrospectively.
RESULTS: Fifty-one patients with WICH were studied. The mean age was 74.3 ± 10.5 years and 52.9% of the patients were female. The mean international normalized ratio (INR) on presentation was 2.9 ± 1.0. The median ICH volume was 23·3 (10·4-59·3) ml. The mortality rate at 3-6 months for WICH was 62·0%. Multivariate logistic analysis revealed that an initial ICH volume of > 20 ml (OR 34·4, P  =  0·037) and presence of intraventricular hemorrhage (OR 22.9, P  =  0·046) were independently associated with poor outcome. Supratherapeutic INR (INR > 3.0) on admission (P  =  0.724) and complete correction of INR within 24 hours after admission (P  =  0·486) were not independent predictors of poor outcome. The median ICH volumes did not differ between INR groups (18·2 (9·4-61·1) ml for INR ≤ 3 vs 27.3 (13.7-58.5) ml for INR > 3, P  =  0·718). Neurological deterioration (ND) was documented in 19 (63·3%) of the 30 patients included in a smaller sub-cohort, and was associated with poor neurological outcome (OR 20·7, P  =  0·027). Warfarin was resumed in 7 of the 20 survivors. There were two episodes of recurrent WICH and one episode of ischemic stroke during a mean follow-up duration of 5·4 years. In survivors who were not resumed on warfarin, there were two episodes of recurrent ICH and 12 episodes of ischemic vascular events (nine ischemic strokes) during a mean follow-up duration of 2·6 years.
CONCLUSION: Warfarin-associated intracerebral hemorrhage is a very serious complication of warfarin therapy with high mortality and morbidity. Initial ICH volume, presence of intraventricular hemorrhage, and ND are independent predictors of clinical outcome.

Entities:  

Keywords:  ICH volume,; Intracerebral hemorrhage,; Intraventricular extension,; Mortality,; Neurological deterioration; Warfarin,; Warfarin-associated ICH,

Mesh:

Substances:

Year:  2013        PMID: 24172661     DOI: 10.1179/1743132813Y.0000000275

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  5 in total

1.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.

Authors:  Daniel M Witt; Robby Nieuwlaat; Nathan P Clark; Jack Ansell; Anne Holbrook; Jane Skov; Nadine Shehab; Juliet Mock; Tarra Myers; Francesco Dentali; Mark A Crowther; Arnav Agarwal; Meha Bhatt; Rasha Khatib; John J Riva; Yuan Zhang; Gordon Guyatt
Journal:  Blood Adv       Date:  2018-11-27

2.  Impact of Antithrombotic Therapy in Atrial Fibrillation on the Presentation of Coronary Artery Disease.

Authors:  Pak Hei Chan; Wen Hua Li; Jo Jo Hai; Hung Fat Tse; Chung Wah Siu
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

Review 3.  Indirect comparison of novel Oral anticoagulants among Asians with non-Valvular atrial fibrillation in the real world setting: a network meta-analysis.

Authors:  Jianchao Zhang; Junnan Tang; Xiaolin Cui; Bo Wang; Mengsen Bu; Yan Bai; Kai Wang; Jiacheng Guo; Deliang Shen; Jinying Zhang
Journal:  BMC Cardiovasc Disord       Date:  2019-07-31       Impact factor: 2.298

4.  Resuming anticoagulants after anticoagulation-associated intracranial haemorrhage: systematic review and meta-analysis.

Authors:  Zien Zhou; Jie Yu; Cheryl Carcel; Candice Delcourt; Jiehui Shan; Richard I Lindley; Bruce Neal; Craig S Anderson; Maree L Hackett
Journal:  BMJ Open       Date:  2018-05-14       Impact factor: 2.692

5.  Protocol, rationale and design of DAbigatran for Stroke PreVention In Atrial Fibrillation in MoDerate or Severe Mitral Stenosis (DAVID-MS): a randomised, open-label study.

Authors:  Mi Zhou; Esther W Chan; Jo Jo Hai; Chun Ka Wong; Yuk Ming Lau; Duo Huang; Cheung Chi Lam; Chor Cheung Frankie Tam; Yiu Tung Anthony Wong; See Yue Arthur Yung; Ki Wan Kelvin Chan; Yingqing Feng; Ning Tan; Ji-Yan Chen; Chi Yui Yung; Kwok Lun Lee; Chun Wai Choi; Ho Lam; Andrew Ng; Katherine Fan; Man Hong Jim; Kai Hang Yiu; Bryan P Yan; Chung Wah Siu
Journal:  BMJ Open       Date:  2020-09-25       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.